Buserelin Acetate can be used as the primary treatment for advanced or metastatic prostate cancer, lowering testosterone levels to delay disease progression and relieve symptoms. It is also effective when combined with surgical castration or anti-androgen therapy, enhancing testosterone suppression, reducing tumor growth, and improving overall outcomes.

Buserelin Acetate suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby lowering testosterone production in the testes. This hormone deprivation strategy effectively inhibits the growth of androgen-dependent prostate cancer cells, providing a targeted therapeutic approach.

Buserelin Acetate is valuable in surgical management of prostate cancer:

• Neoadjuvant therapy: Reduces tumor size before surgery, easing removal and lowering the risk of cancer spread.
• Adjuvant therapy: Used post-surgery to eliminate residual cancer cells and prevent recurrence, improving long-term outcomes.

Potential side effects include hot flashes, decreased libido, erectile dysfunction, lethargy, and mood swings. Long-term use may reduce bone density, so continuous monitoring by healthcare providers is essential to manage side effects and ensure patient safety.

Buserelin Acetate's targeted testosterone suppression enhances prostate cancer treatment. It improves surgical outcomes, slows disease progression, and enhances patient quality of life. Ongoing research continues to refine its use, offering promise for better patient outcomes.